Investigating the Efficacy of Dynamic Temporal and Tactile Cueing in Stroke Patients with Apraxia of Speech: A Study Protocol Using a Single-Subject Design

Maryam  Alizadeh; Azar  Mehri; Shohreh  Jalaie; Edythe A.  Strand

doi:10.18502/jmr.v20i2.21714

Maryam Alizadeh Department of Speech Therapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.
Azar Mehri Department of Speech Therapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.
Shohreh Jalaie Department of Physiotherapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.
Edythe A. Strand Mayo College of Medicine, Rochester, United States of America.

DOI: https://doi.org/10.18502/jmr.v20i2.21714

Keywords: Acquired apraxia of speech; Dynamic temporal and tactile cueing; Stroke

Abstract

Introduction: Dynamic temporal and tactile cueing (DTTC) is a treatment method for childhood apraxia of speech (AOS), and its characteristics make it a suitable option for treating patients with AOS. Additionally, no documented treatment protocol has been published in Iran for the treatment of patients with AOS. This study protocol aims to investigate the efficacy of DTTC in the treatment of Persian-speaking patients with acquired AOS, who will be recruited using non-probability, convenience sampling.

Materials and Methods: A single-subject study with multiple baseline designs across participants was designed to obtain detailed information about the intervention procedure on at least three participants’ performance, and a perceptual scoring system was introduced to measure the accuracy of treated and untreated words and phrases as a dependent variable.

Results: The results of a visual analysis will be provided based for the assessment of participants at three phases of baseline, treatment, and follow-up, and the effect sizes will be reported.

Conclusion: This study describes the first research investigating the efficacy of DTTC on the speech of AOS patients and the first treatment protocol for Persian-speaking patients with AOS.